Enhanced anticancer efficacy of docetaxel through galbanic acid encapsulated into PLA-PEG nanoparticles in treatment of colon cancer,in vitro and in vivo study
Restricted accessResearch articleFirst published online November, 2021
Enhanced anticancer efficacy of docetaxel through galbanic acid encapsulated into PLA-PEG nanoparticles in treatment of colon cancer,in vitro and in vivo study
Cancer is one of the most leading causes of human mortality and despite outstanding breakthrough in introducing new therapeutic approaches, the clinical outcomes are disappointing. Therefore, extensive research in design and preparation of more efficient drug delivery systems can open a window to shine light into the therapeutic modality. In this study, we evaluated the effect of galbanic acid (GBA) encapsulated into PLA-PEG nanoparticles (NPs) to enhanced anticancer efficacy of docetaxel (DOC) for the treatment of colon cancer. Prepared NPs were characterized by different methods in terms of size, zeta potential, and drug loading capacity. MTT assay was used to investigate the anti-proliferation of GBA-loaded PEG-PLA NPs along with DOC. The therapeutic efficacy of PEG-PLA@GBA NPs & DOC was further investigated in C26 tumor-bearing BALB/c mice model. The resulting NPs were narrowly distributed (PDI = 0.06) with the mean diameter of 148 ± 9 nm with somewhat negative charge. GBA were efficiently loaded into mPEG-PLA NPs with encapsulation efficiency of about 40% ± 3. Cytotoxicity studies showed that NPs loaded with GBA and fixed concentration of docetaxel (20 nM) have higher toxicity (IC50 = 6 ± 1.8 µM) than either PEG-PLA@GBA (IC50 = 8 ± 1.2 µM) or free GBA (IC50 = 15 ± 3.5 µM) in C26 cells. In vivo studies revealed a synergistic effect of PEG-PLA@GBA NPs and DOC on tumor growth inhibition and survival rate in comparison with monotherapy approach.
ZhangRXWongHLXueHY, et al. Nanomedicine of synergistic drug combinations for cancer therapy: strategies and perspectives. J Controlled Release2016; 240: 489–503.
2.
SannaVPalaNSechiM.Targeted therapy using nanotechnology: focus on cancer. Int J Nanomed2014; 9: 467–483.
3.
TrabuloSCardosoAMSantos-FerreiraT, et al. Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents. Mol Pharm2011; 8(4): 1120–1131.
4.
de Oliveira JúniorRGChristiane AdriellyAFda Silva AlmeidaJRG, et al. Sensitization of tumor cells to chemotherapy by natural products: a systematic review of preclinical data and molecular mechanisms. Fitoterapia2018; 129: 383–400.
5.
FarokhzadOCLangerR.Impact of nanotechnology on drug delivery. ACS Nano2009; 3(1): 16–20.
6.
ShresthaBTangLRomeroG.Nanoparticles-mediated combination therapies for cancer treatment. Adv Ther2019; 2(11): 1900076.
7.
KimBYRutkaJTChanWC.Nano-medicine. N Engl J Med2010; 363(25): 2434–2443.
8.
ZhangLGuFChanJ, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther2008; 83(5): 761–769.
9.
BabaeiMAbnousKTaghdisiSM, et al. Synthesis of theranostic epithelial cell adhesion molecule targeted mesoporous silica nanoparticle with gold gatekeeper for hepatocellular carcinoma. Nanomedicine2017; 12(11): 1261–1279.
10.
EbrahimianMHashemiMMalekiM, et al. Co-delivery of dual toll-like receptor agonists and antigen in poly(lactic-co-glycolic) acid/polyethylenimine cationic hybrid nanoparticles promote efficient in vivo immune responses. Front Immunol2017; 8: 1077.
11.
WangJLiSHanY, et al. Poly(ethylene glycol)-polylactide micelles for cancer therapy. Front Pharmacol2018; 9: 202.
12.
KimuraY.Antitumor and vascular physiological effects of natural products. Stud Nat Prod Chem2005; 30: 55–78.
13.
KimuraY.Antitumor and antimetastatic actions of various natural products. Stud Nat Prod Chem2008; 34: 35–76.
14.
ShiJXiaoZKamalyN, et al. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Account Chem Res2011; 44(10): 1123–1134.
15.
TylerBGullottiDMangravitiA, et al. Polylactic acid (PLA) controlled delivery carriers for biomedical applications. Adv Drug Deliv Rev2016; 107: 163–175.
16.
LammersTKiesslingFHenninkWE, et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Controlled Release2012; 161(2): 175–187.
17.
AlexisFPridgenEMolnarLK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm2008; 5(4): 505–515.
18.
JokerstJVLobovkinaTZareRN, et al. Nanoparticle PEGylation for imaging and therapy. Nanomedicine2011; 6(4): 715–728.
19.
KnopKHoogenboomRFischerD, et al. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl2010; 49(36): 6288–6308.
20.
ChowEKHoD.Cancer nanomedicine: from drug delivery to imaging. Sci Transl Med2013; 5(216): 216rv4.
21.
ZhangLZhangN.How nanotechnology can enhance docetaxel therapy. Int J Nanomedicine2013; 8: 2927–2941.
22.
ValiahdiSMIranshahiMSahebkarA.Cytotoxic activities of phytochemicals from Ferula species. Daru2013; 21(1): 39.
23.
ShahverdiARFakhimiAZarriniG, et al. Galbanic acid from Ferula szowitsiana enhanced the antibacterial activity of penicillin G and cephalexin against Staphylococcus aureus. Biol Pharm Bull2007; 30(9): 1805–1807.
24.
OhBSShinEAJungJH, et al. Apoptotic effect of galbanic acid via activation of caspases and inhibition of mcl-1 in H460 non-small lung carcinoma cells. Phytother Res2015; 29(6): 844–849.
25.
EskandaniMBararJDolatabadiJE, et al. Formulation, characterization, and geno/cytotoxicity studies of galbanic acid-loaded solid lipid nanoparticles. Pharm Biol2015; 53(10): 1525–1538.
26.
AfsharzadehMHashemiMBabaeiM, et al. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells. J Cell Physiol2020; 235: 4618–4630.
27.
KasaianJIranshahyMIranshahiM.Synthesis, biosynthesis and biological activities of galbanic acid: a review. Pharm Biol2014; 52(4): 524–531.
28.
AfsharzadehMAbnousKYazdian-RobatiR, et al. Formulation and evaluation of anticancer and antiangiogenesis efficiency of PLA-PEG nanoparticles loaded with galbanic acid in C26 colon carcinoma, in vitro and in vivo. J Cell Physiol2019; 234(5): 6099–6107.
29.
AfsharzadehMHashemiMBabaeiM, et al. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells. J Cell Physiol2020;235(5):4618–4630.
30.
HansMShimoniKDaninoD, et al. Synthesis and characterization of mPEG-PLA prodrug micelles. Biomacromolecules2005; 6: 2708–2717.
31.
MoghimiSMPorterCJMuirIS, et al. Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem Biophys Res Commun1991; 177(2): 861–866.
32.
GreishK.Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine: are we there yet?Drug Discov Today Technol2012; 9(2): e161–e166.
33.
HeQChenJYanJ, et al. Tumor microenvironment responsive drug delivery systems. Asian J Pharm Sci2020; 15(4): 416–448.
34.
YuWLiuRZhouY, et al. Size-Tunable strategies for a tumor targeted drug delivery system. ACS Cent Sci2020; 6(2): 100–116.
35.
GrefRDombAQuellecP, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev1995; 16(2–3): 215–233.
36.
LiQXiongYJiC, et al. The application of nanotechnology in the codelivery of active constituents of plants and chemotherapeutics for overcoming physiological barriers during antitumor treatment. Biomed Res Int2019; 2019: 9083068.
37.
GuoXZhaoZChenD, et al. Co-delivery of resveratrol and docetaxel via polymeric micelles to improve the treatment of drug-resistant tumors. Asian J Pharm Sci2019; 14(1): 78–85.
38.
PezzaniRSalehiBVitaliniS, et al. Synergistic effects of plant derivatives and conventional chemotherapeutic agents: an update on the cancer perspective. Medicina2019; 55(4): 110.
39.
BonettoARupertJEBarretoR, et al. The Colon-26 carcinoma tumor-bearing mouse as a model for the study of cancer cachexia. J Vis Exp2016; 117: 54893.
40.
AulinoPBerardiECardilloVM, et al. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer2010; 10: 363.
41.
ZhouYLiKLiF, et al. Doxorubicin and ABT-199 coencapsulated nanocarriers for targeted delivery and synergistic treatment againstHepatocellular carcinoma. J Nanomater2019; 2019: 5274598.
42.
WangHZhaoYWuY, et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials2011; 32(32): 8281–8290.
43.
DongXYLangTQYinQ, et al. Co-delivery of docetaxel and silibinin using pH-sensitive micelles improves therapy of metastatic breast cancer. Acta Pharmacol Sin2017; 38(12): 1655–1662.
